These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12603692)

  • 1. Epstein-Barr virus associated disease following blood or marrow transplant.
    Gross TG; Loechelt BJ
    Pediatr Transplant; 2003; 7 Suppl 3():44-50. PubMed ID: 12603692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
    O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L
    Springer Semin Immunopathol; 1998; 20(3-4):455-91. PubMed ID: 9870257
    [No Abstract]   [Full Text] [Related]  

  • 4. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
    Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease.
    Bollard CM; Savoldo B; Rooney CM; Heslop HE
    Acta Haematol; 2003; 110(2-3):139-48. PubMed ID: 14583674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis.
    Tanner JE; Alfieri C
    Transpl Infect Dis; 2001 Jun; 3(2):60-9. PubMed ID: 11395971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
    Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
    Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
    Hoffmann T; Russell C; Vindelov L
    APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management.
    Smets F; Sokal EM
    Pediatr Transplant; 2002 Aug; 6(4):280-7. PubMed ID: 12234267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus and post-transplant lymphoproliferative disease.
    Holmes RD; Sokol RJ
    Pediatr Transplant; 2002 Dec; 6(6):456-64. PubMed ID: 12453197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients.
    Köpf S; Tönshoff B
    Pediatr Nephrol; 2004 Apr; 19(4):365-8. PubMed ID: 14963763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
    Hao QF; Sheng GY; Luan Z
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):795-9. PubMed ID: 24034931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
    Martinez OM; Krams SM
    Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
    Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV specific CTL: a model for immune therapy.
    Rooney CM; Heslop HE; Brenner MK
    Vox Sang; 1998; 74 Suppl 2():497-8. PubMed ID: 9704488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus and bone marrow transplantation.
    Caldas C; Ambinder R
    Curr Opin Oncol; 1995 Mar; 7(2):102-6. PubMed ID: 7756374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.